AlphAIAlphAI — Financial news for AI agents
investing.comOCT 62 min read$SGRY

Cantor Fitzgerald reiterates Surgery Partners stock Overweight rating

Cantor Fitzgerald reiterated an Overweight rating on Surgery Partners (SGRY) with a $18.00 price target, implying 35% upside. The stock has declined 35% over the past year. Analysts forecast earnings of $0.32 per share for 2026. Q2 2026 results showed a larger-than-expected loss but revenue beat expectations at $848.9 million. Benchmark reiterated a Buy rating with a $24 price target, citing portfolio optimization.

Original reporting
investing.com
Published Oct 6, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SGRY
Neutral
medium confidence
Mentioned
$SGRY
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SGRYNeutralMed
01

Why it matters

The new earnings miss and guidance revision create a mixed signal for traders, with potential short‑term downside but longer‑term upside from the divestiture proceeds.

02

Market read

Analyst rating and fresh earnings data provide a fresh catalyst for SGRY, making it a candidate for short‑term trade based on the earnings miss versus the positive rating.

03

What to watch

Flat outpatient openings and reduced bonus spend suggest operational headwinds that may limit near‑term upside.

Relevance 6/10Novelty 6/10Timing: pre-market today

Background

The article is an analyst note reiterating an Overweight rating for Surgery Partners (SGRY) and providing updated earnings forecasts and recent Q2 results.

Company-level read

Ticker impact

$SGRYNeutralMedium confidence
Context

Cantor Fitzgerald reiterated Overweight on Surgery Partners with an $18 price target and reported Q2 adjusted loss of $0.12 per share versus expectations of a $0.06 profit.

Expected impact

possible downward pressure as the earnings miss outweighs the positive rating, but upside potential remains if the Idaho Falls divestiture proceeds as expected.

Evidence & confidence

The downgrade in earnings contradicts the Overweight rating; investors may react negatively to the loss, yet the $795 M divestiture proceeds could support the stock.

Market effects

Sector

Surgery Partners' performance may influence other ambulatory surgery center operators and healthcare REITs.

Regional

U.S. healthcare sector may see modest re‑rating as analysts adjust expectations.

Global

Limited to U.S. healthcare equities.

Counterpoint

What could challenge this read

Despite the earnings miss, the sizable Idaho Falls hospital sale could unlock cash and drive a rebound.

Key entities

  • Company
    Surgery Partners

    Operator of ambulatory surgery centers in the United States.

  • Analyst
    Cantor Fitzgerald

    Equity research firm reiterating Overweight rating.

Read at source← All news

Related articles

SEP 17
$SGRYMed

Surgery Partners, Inc. (SGRY): Completion of Acquisition or Disposition of Assets

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. SURGERY PARTNERS, INC. Unaudited Pro Forma Condensed Consolidated Financial Statements On September 14, 2026, Surgery Partners, Inc. (the "Company"), through certain of its subsi diaries, entered into two Securities Purchase Agreements (the "Agreements") to sell it's ownership in

SEC EDGAR 8-K2 min
AUG 17
$SGRYMedAI 8/10

Surgery Partners (SGRY) Q2 2026 Earnings Call Transcript

Surgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.

yahoo.com8 min
AUG 11
$SGRYMed

Surgery Partners: Q2 Earnings Snapshot

Surgery Partners Inc. (SGRY) reported a Q2 loss of $15 million, or 12 cents per share. Adjusted earnings were 10 cents per share, and revenue was $848.9 million. The company expects full-year revenue of $3.35 billion to $3.45 billion, according to its earnings release.

local3news.com2 min
AUG 10
$SGRYMed

Surgery Partners Q2 Earnings Call Highlights

Surgery Partners (NASDAQ:SGRY) reported Q2 same-facility revenue up 4.9% for the first half, driven by a 0.8% case increase and 4% net revenue per case. Management said commercial payer mix fell to about 49% of Q2 net revenue, with government payments rising. The company signed agreements to sell Idaho Falls assets for about $795M gross consideration and reaffirmed 2026 guidance excluding the deal.

finance.yahoo.com6 min
AUG 10
$SGRYMed

Surgery Partners shares edge lower despite Q2 revenue beat

Surgery Partners (NASDAQ:SGRY) shares fell 0.71% pre-market after Q2 results were mixed. Revenue rose to $848.9M, above the $830.05M forecast, and same-facility revenue grew 5%. Adjusted EPS was $0.10 vs $0.06 consensus, but GAAP net loss was $0.12/share. Adjusted EBITDA fell to $125.2M. Company reaffirmed 2026 revenue $3.35B-$3.45B and adjusted EBITDA at least $530M.

finance.yahoo.com4 min